Epidemiology of HIV-associated peripheral neuropathy in people living with human immunodeficiency virus infection in Greece.


Journal

International journal of STD & AIDS
ISSN: 1758-1052
Titre abrégé: Int J STD AIDS
Pays: England
ID NLM: 9007917

Informations de publication

Date de publication:
Oct 2022
Historique:
pubmed: 18 8 2022
medline: 13 10 2022
entrez: 17 8 2022
Statut: ppublish

Résumé

Peripheral neuropathy is among the most common complications among people with HIV with prevalence rates varying widely among studies (10-58%). This study aims to assess the prevalence of HIV-associated peripheral neuropathy among HIV-positive people in Northern Greece monitored during the last 5-year period and investigate possible correlations with antiretroviral therapy, disease staging, and potential risk factors, as there is no prior epidemiological record in Greek patients. Four hundred twenty patients were divided into a group with peripheral neuropathy ( The incidence of peripheral neuropathy was estimated at 35.9%. Age was found to correlate with higher odds of developing HIV-peripheral neuropathy, rising by 4%/year. Females encountered 77% higher probability to develop peripheral neuropathy. Stage 3 of the disease associated with higher occurrence of peripheral neuropathy (96% as compared to stage-1 patients). Among patients with peripheral neuropathy, the duration of antiretroviral therapy was found to be longer than in those without. Peripheral neuropathy remains one of the most common complications regardless of the antiretroviral-therapy type, indicating the involvement of other risk factors in its occurrence, such as the stage of the disease, age and gender. Therefore, the treating physician should screen patients as early and frequently as possible upon HIV-diagnosis to prevent the progression of this debilitating condition so that prolonged life-expectancy is accompanied by a good quality of life.

Sections du résumé

BACKGROUND
Peripheral neuropathy is among the most common complications among people with HIV with prevalence rates varying widely among studies (10-58%).
OBJECTIVE
This study aims to assess the prevalence of HIV-associated peripheral neuropathy among HIV-positive people in Northern Greece monitored during the last 5-year period and investigate possible correlations with antiretroviral therapy, disease staging, and potential risk factors, as there is no prior epidemiological record in Greek patients.
METHODS
Four hundred twenty patients were divided into a group with peripheral neuropathy (
RESULTS
The incidence of peripheral neuropathy was estimated at 35.9%. Age was found to correlate with higher odds of developing HIV-peripheral neuropathy, rising by 4%/year. Females encountered 77% higher probability to develop peripheral neuropathy. Stage 3 of the disease associated with higher occurrence of peripheral neuropathy (96% as compared to stage-1 patients). Among patients with peripheral neuropathy, the duration of antiretroviral therapy was found to be longer than in those without.
CONCLUSIONS
Peripheral neuropathy remains one of the most common complications regardless of the antiretroviral-therapy type, indicating the involvement of other risk factors in its occurrence, such as the stage of the disease, age and gender. Therefore, the treating physician should screen patients as early and frequently as possible upon HIV-diagnosis to prevent the progression of this debilitating condition so that prolonged life-expectancy is accompanied by a good quality of life.

Identifiants

pubmed: 35975977
doi: 10.1177/09564624221119305
doi:

Substances chimiques

Anti-Retroviral Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

978-986

Auteurs

Ioannis Nikolaidis (I)

Second Department of Neurology, AHEPA University General Hospital--Department of Neurosciences, 37782Aristotle University--School of Medicine, Thessaloniki, Greece.

Maria-Valeria Karakasi (MV)

Third Department of Psychiatry, AHEPA University General Hospital-Department of Mental Health, 37782Aristotle University--School of Medicine, Thessaloniki, Greece.

Christos Bakirtzis (C)

Second Department of Neurology, AHEPA University General Hospital--Department of Neurosciences, 37782Aristotle University--School of Medicine, Thessaloniki, Greece.

Lemonia Skoura (L)

First Department of Internal Medicine, AHEPA University General Hospital--37782Aristotle University--School of Medicine, Thessaloniki, Greece.

Dimitrios Pilalas (D)

First Department of Internal Medicine, AHEPA University General Hospital--37782Aristotle University--School of Medicine, Thessaloniki, Greece.

Marina-Kleopatra Boziki (MK)

Second Department of Neurology, AHEPA University General Hospital--Department of Neurosciences, 37782Aristotle University--School of Medicine, Thessaloniki, Greece.

Olga Tsachouridou (O)

First Department of Internal Medicine, AHEPA University General Hospital--37782Aristotle University--School of Medicine, Thessaloniki, Greece.

Polychronis Voultsos (P)

Bioethics, Department of Forensic Medicine and Toxicology, 37782Aristotle University--Faculty of Medicine, Thessaloniki, Greece.

Pavlos Nikolaidis (P)

First Department of Internal Medicine, AHEPA University General Hospital--37782Aristotle University--School of Medicine, Thessaloniki, Greece.

Panagiotis Gargalianos-Kakoliris (P)

Infectious Disease Unit, Athens Medical Group, Athens, Greece.

Michail Daniilidis (M)

First Department of Internal Medicine, AHEPA University General Hospital--37782Aristotle University--School of Medicine, Thessaloniki, Greece.

Nikolaos Grigoriadis (N)

Second Department of Neurology, AHEPA University General Hospital--Department of Neurosciences, 37782Aristotle University--School of Medicine, Thessaloniki, Greece.

Symeon Metallidis (S)

First Department of Internal Medicine, AHEPA University General Hospital--37782Aristotle University--School of Medicine, Thessaloniki, Greece.

Nikolaos Taskos (N)

Second Department of Neurology, AHEPA University General Hospital--Department of Neurosciences, 37782Aristotle University--School of Medicine, Thessaloniki, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH